Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.
By E. Perez, E. Romond, V. Suman, Jong-Hyeon Jeong, G. Sledge, C. Geyer, S. Martino, P. Rastogi, J. Gralow, S. Swain and 6 more. Journal of Clinical Oncology, 2014
899 citations recorded by the source corpus.
Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/a24b1f4ab806763104928097b4ccdd256b620ebf
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- F. Penault-Llorca
- E. Senkus
- F. Cardoso
- P. Poortmans
- S. Kyriakides
- S. Ohno
- S. Zackrisson
- E. Rutgers
Citations in the corpus
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015, background): “to be more effective than sequential treatment [I, A] [128].”